Neumora Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -8 | -5,000 | ||
EBITDA | -51,566 | -57,405 | -55,985 | -52,687 |
EBIT | -51,574 | -57,414 | -56,008 | -52,706 |
Net Income | -53,458 | -59,450 | -56,755 | -52,731 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -46,404 | -47,939 | -46,649 | -52,404 |
Cash | 147,072 | 182,530 | 129,071 | 124,523 |
Basic Shares | 179,872 | 163,391 | 161,838 | 161,691 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -5,000 | -668 | -2,697 | |
EBITDA | -233,371 | -242,978 | -234,989 | -130,310 |
EBIT | -233,579 | -243,609 | -235,657 | -130,904 |
Net Income | -236,928 | -243,787 | -235,925 | -130,904 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -206,440 | -182,936 | -163,395 | -115,407 |
Cash | 182,530 | 142,148 | 374,038 | 240,943 |
Basic Shares | 163,391 | 159,377 | 158,832 | 151,949 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.33 |
2026-03-31 | -$0.30 |
2025-12-31 | -$0.35 |
2025-09-30 | -$0.35 |